Bayer AG 's voluntary withdrawal in August of cholesterol-lowering cerivastatin (Baycol/Lipobay) increased the already strong pressure on the 130-year-old German chemicals conglomerate to let go of its four-pillar structure combining Chemicals, Polymers, Agriculture and Health Care. As compatriots have streamlined their businesses—BASF AG took $6.9 billion in cash last year for its pharmaceuticals business from Abbott Laboratories Inc. [See Deal] and picked up American Home Products Corp. 's agrochemicals business Cyanamid, while Hoechst AG sold off its non-life sciences businesses in 1998 before merging with France's Rhône-Poulenc Rorer to form Aventis SA [See Deal]—Bayer has hung stubbornly on to its diverse operations. Last year, these posted sales of €31 billion, of which one third were in Health Care.
The company announced the withdrawal of Baycol, its second biggest drug, on August 8th, after reports of 52 deaths linked...





